BioLineRx Ltd. Reports Q2 2024 Financial Results

TL;DR

BioLineRx dropped Q2 earnings on Aug 15, 2024. Check the 6-K for details.

AI Summary

BioLineRx Ltd. announced its financial results for the three and six months ended June 30, 2024, on August 15, 2024. The company, headquartered at 2 HaMa'ayan Street, Modi'in, Israel, filed a Form 6-K report with the SEC. This filing includes their unaudited interim consolidated financial statements and operating information.

Why It Matters

This filing provides investors with an update on BioLineRx's financial performance and operational status for the second quarter of 2024, crucial for assessing the company's current health and future prospects.

Risk Assessment

Risk Level: medium — As a foreign private issuer in the pharmaceutical sector, BioLineRx faces inherent risks related to drug development, regulatory approvals, and market competition, which are amplified by its international operations.

Key Players & Entities

• BioLineRx Ltd. (company) — Registrant
• August 15, 2024 (date) — Date of press release and filing
• June 30, 2024 (date) — End of reporting period
• 2 HaMa'ayan Street, Modi'in, Israel (location) — Principal Executive Offices

FAQ

Filing Documents

• zk2431827.htm (6-K) — 15KB
• exhibit_1.htm (EX-99) — 349KB
• exhibit_2.htm (EX-99.2) — 734KB
• exhibit_3.htm (EX-3) — 273KB
• image00001.jpg (GRAPHIC) — 35KB
• 0001178913-24-002633.txt ( ) — 3762KB
• blrx-20240630.xsd (EX-101.SCH) — 51KB
• blrx-20240630_cal.xml (EX-101.CAL) — 35KB
• blrx-20240630_def.xml (EX-101.DEF) — 60KB
• blrx-20240630_lab.xml (EX-101.LAB) — 413KB
• blrx-20240630_pre.xml (EX-101.PRE) — 145KB
• zk2431827_htm.xml (XML) — 400KB

From the Filing

BioLineRx Ltd. - 1498403 - 2024 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant's name into English) 2 HaMa'ayan Street Modi'in 7177871 , Israel (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F On August 15, 2024, the Registrant issued a press release announcing its financial results for the three and six months ended June 30, 2024. The Registrant is also publishing its unaudited interim consolidated financial statements, as well as its operating and financial review, as of June 30, 2024 and for the three and six months then ended. Attached hereto are the following exhibits: Exhibit 1: Registrant's press release dated August 15, 2024; Exhibit 2: Registrant's condensed consolidated interim financial statements as of June 30, 2024 and for the three and six months then ended; and Exhibit 3: Registrant's operating and financial review as of June 30, 2024 and for the three and six months then ended. This Form 6-K, the text under the heading "Second Quarter 2024 Financial Results" in Exhibit 1, Exhibit 2 and Exhibit 3 are hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioLineRx Ltd. By: /s/ Philip A. Serlin Philip A. Serlin Chief Executive Officer Dated: August 15, 2024

View Full Filing

View this 6-K filing on SEC EDGAR